1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position
摘要:
The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.
Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of:
wherein the variables are as defined herein.
提供了用于与包含以下化合物的激酶一起使用的化合物、药物组合物和试剂盒:
其中变量的定义如本文所述。
KINASE INHIBITORS
申请人:Dong Qing
公开号:US20100216765A1
公开(公告)日:2010-08-26
Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of:
wherein the variables are as defined herein.
Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders
申请人:Bruce Ian
公开号:US20140051698A1
公开(公告)日:2014-02-20
The present invention concerns a compound of formula (I)
or a pharmaceutically acceptable salt or solvate thereof, where R
1
-R
3
and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders
申请人:Novartis AG
公开号:US08901134B2
公开(公告)日:2014-12-02
The present invention concerns a compound of formula (I)
or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS
申请人:Bloomfield Graham Charles
公开号:US20140235632A1
公开(公告)日:2014-08-21
The present invention concerns a compound of formula (I)
or a pharmaceutically acceptable salt or solvate thereof, where R
1
-R
3
and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.